ClinicalTrials.gg
RecruitingNCT05244109TEARE-BIOUpdated Jun 1, 2022

Biomedicines and Bacterial Translocation in Spondyloarthritis

An interventional study of Blood sample and anti-TNF antibody administration in Axial Spondyloarthritis, sponsored by Centre Hospitalier Universitaire de Besancon. Recruiting at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-06-01.

Sponsored by Centre Hospitalier Universitaire de Besancon · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Started Feb 2022; still recruiting 4 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Axial Spondyloarthritis with a site in France — 9 open to participants now, 11 under way, 3 of them phase 3. Axial Spondyloarthritis · France.

Planned enrollment
21st of 30
90 · median 188
Started
2022
with 2 others
No phase
13 of 40
6 open now
Primary completion
2025-02
later than 1 of 10 live
Registered
29th of 40
by date
Lead sponsor
4 of 40
Centre Hospitalier Universitaire de Besancon

Among the 40 studies in Axial Spondyloarthritis with a site in France, this one is the 21st largest by planned enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2022, is one of 13 with no phase, reaches primary completion later than 1 of the 10 other live ones, and was the 29th registered.

Axial Spondyloarthritis

187 studies on the registry are indexed under Axial Spondyloarthritis; 57 are open to participants now.

Browse Axial Spondyloarthritis studies →

Open to participants now

9 of the 40 studies in Axial Spondyloarthritis with a site in France are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 39 Axial Spondyloarthritis studies recruiting now, 20 (51%) set no upper age limit and 13 (33%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Axial Spondyloarthritis with a site in France, or all of them as a file.
02

Study summary

The aim of this project is to evaluate the effect of anti-TNF and anti-IL17 biotherapies on bacterial translocation in patients with NSAID-resistant axial spondyloarthritis.

Read the detailed description

Axial spondyloarthritis is a common inflammatory rheumatic disease and its management is based on the use of NSAIDs and biotherapies (anti-TNF and anti-IL17 antibodies). Its pathophysiology involves the digestive mucosa. The colon of patients with spondyloarthritis is the site of asymptomatic inflammation. This inflammation results from dysbiosis, which is responsible for activation of innate immunity linked to bacterial translocation phenomena. Dendritic cells are then activated and the immune response is polarized towards the IL23/Th17 axis. This translocation is secondary to an increase in colonic permeability. The increase in digestive permeability allows translocation of bacteria or bacterial fragments, primarily lipopolysaccharide (LPS).

Some proinflammatory cytokines (TNF, IFNγ, and IL23) cause an increase in digestive permeability. IL17 produced in the digestive mucosa has two different effects. Indeed, two types of colonic T cells produce IL17: regulatory T Helpers 17 producing IL10 and IL17 and inflammatory T Helpers 17 producing IL17 and IFNγ.

The investigators hypothesize that biotherapies decrease bacterial translocation. They suspect a lesser effect of anti-IL17 compared to anti-TNF because of the potential inhibition of Treg17 lymphocytes.

03

Conditions studied

  • Axial Spondyloarthritis

Keywords

  • bacterial translocation
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Axial spondyloarthritis (2009 ASAS criteria)
  • NSAID arm: Responding to any class of NSAID and not likely to initiate biotherapy
  • anti-TNF/anti-IL-17 arms: Need to introduce a biomedical drug according to current recommendations (objective signs of inflammation, i.e. MRI sacroiliitis or increased CRP, and failure of two NSAIDs of different classes)

Exclusion criteria

Exclusion Criteria:

  • IBD already diagnosed by a gastroenterologist or suspicion of IBD (bloody diarrhea)
  • Previous exposure to a biomedical drug (anti TNF or anti IL 17).
  • Antibiotic use in the 3 months prior to inclusion
  • for treatment with anti-TNF or anti-IL17 (for all patients)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    NSAIDs

    Patients responding to any class of NSAIDs and unlikely to initiate biotherapy

    Other: Blood sample

  • Experimental
    Anti-TNF antibody

    Patients requiring the introduction of biotherapy according to current recommendations and randomized to the anti-TNF treatment arm

    Other: Blood sample · Drug: anti-TNF antibody administration

  • Experimental
    Anti-IL17 antibody

    Patients requiring the introduction of biotherapy according to current recommendations and randomized to the anti-IL-17 treatment arm

    Other: Blood sample · Drug: anti-IL-17 antibody administration

Interventions

  • OtherBlood sample

    Blood samples (2 times; 21mL per visit)

  • Druganti-TNF antibody administration

    Anti-TNF antibody administration, according to current recommendations and randomization results

  • Druganti-IL-17 antibody administration

    Anti-IL-17 antibody administration, according to current recommendations and randomization results

06

What researchers measure

Primary outcomes

  1. Difference in serum LPS concentration

    Difference in serum LPS concentration, measured by liquid chromatography-mass spectrometry, between D0 (before anti-TNF or anti-IL 17) and D90

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Feb 2025, 36 months after the start.

Of 46 non-industry interventional studies with no phase under Axial Spondyloarthritis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 42. This study's planned 36 months is above that.

Counting every sponsor, half of 46 studies reached it within 28 months; a quarter within 11 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2022
First posted
Feb 17, 2022
StartActual
Feb 7, 2022
Primary completionEst.
Feb 2025
CompletionEst.
May 2025
Last update
Jun 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05244109
Responsible party
Sponsor
First posted
Feb 17, 2022
Start date
Feb 7, 2022
Primary completion
Feb 2025 (estimated)
Completion
May 2025 (estimated)
Last update
Jun 1, 2022

Study contacts

Frank Verhoeven, MD
Contact
fverhoeven@chu-besancon.fr
+33381668241

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion